Jiali Chen1
Ligen Lin- 1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao SAR, China
- 2State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 3Department of Pharmaceutical Sciences and Technology, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, China
Obesity, a complex disease involving an excessive amount of body fat and a major threat to public health all over the world, is the determining factor of the onset and development of metabolic disorders, including type 2 diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease. Long-term overnutrition results in excessive expansion and dysfunction of adipose tissue, inflammatory responses and over-accumulation of extracellular matrix in adipose tissue, and ectopic lipid deposit in other organs, termed adipose tissue remodeling. The mammalian Sirtuins (SIRT1–7) are a family of conserved NAD+-dependent protein deacetylases. Mounting evidence has disclosed that Sirtuins and their prominent substrates participate in a variety of physiological and pathological processes, including cell cycle regulation, mitochondrial biogenesis and function, glucose and lipid metabolism, insulin action, inflammatory responses, and energy homeostasis. In this review, we provided up-to-date and comprehensive knowledge about the roles of Sirtuins in adipose tissue remodeling, focusing on the fate of adipocytes, lipid mobilization, adipose tissue inflammation and fibrosis, and browning of adipose tissue, and we summarized the clinical trials of Sirtuin activators and inhibitors in treating metabolic diseases, which might shed light on new therapeutic strategies for obesity and its associated metabolic diseases.
Introduction
Obesity has reached epidemic proportions globally in the past several decades, in both children and adults (1), which is a major contributor to the explosion of obesity-related metabolic diseases, including non-alcoholic fatty liver disease, cardiovascular diseases, and type 2 diabetes mellitus (2–4). Excessive energy is stored in adipose tissue (AT) in the form of triglycerides (TGs), causing obesity. Pathological AT expansion, which is accompanied by massive enlargement of existing adipocytes, the over-production of extracellular matrix (ECM), inadequate angiogenesis, elevated immune cell accumulation, pro-inflammatory responses, and ectopic lipid deposit, is termed AT remodeling (5). Massive expansion and remodeling of AT occur during obesity, and different AT depots exhibit various scenery (1). Under high-fat diet (HFD) feeding, visceral AT and subcutaneous AT expand through the enlargement of pre-existing adipocytes (hypertrophy) and the recruitment of newly generated adipocytes (hyperplasia), respectively; hyperplasia is metabolically healthy, whereas hypertrophy leads to metabolic complications (6). Adipose progenitors are a heterogeneous group of cells with diverse cell fates, contributing to white and beige adipogenesis, fibrosis, or maintenance of an immature cell phenotype with proliferation capacity. The factors shaping cell fate decisions of adipose progenitor cells determine the onset and development of obesity (7). Lipid mobilization, referring to fatty acid trafficking in (lipogenesis) and out (lipolysis) of the adipocytes, is a paramount process in regulating systemic energy metabolism. Hormone-sensitive lipase (HSL), adipose TG lipase (ATGL), and monoglyceride lipase (MGL) are considered the key rate-limiting enzymes responsible for lipolysis in adipocytes (8).
ECM components, such as fibronectin and collagen, provide mechanical support for hypertrophic adipocytes, while abnormal production and deposition of ECM cause the destruction of normal AT structure and impaired tissue flexibility in obese subjects (9). Adipocyte stress and death, and the formation of inflammatory foci occur when hypertrophic adipocytes lack proper ECM support (10). Evidence suggests that macrophages are the predominant leukocytes in AT, and the proportion of macrophages increases from approximately 5% in lean AT to more than 50% in obese AT (11). In addition, AT inflammation is accompanied by the shift from the alternatively activated macrophage (M2) phenotype to the classically activated macrophage (M1) phenotype in obese subjects (12). M1 macrophages secrete various pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and chemokines, such as monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α (MIP-1α). Infiltration and pro-inflammatory polarization of macrophages are determining factors of systemic inflammation and insulin resistance (IR) (13). Therefore, AT inflammation and abnormal ECM deposition play critical roles in obesity-induced metabolic disorders (14, 15). Unlike white AT, which stores energy, brown AT contains large amounts of mitochondria and dissipates lipids as heat by uncoupling protein 1 (UCP1) to maintain body temperature. Beige cells arise as multilocular adipocytes and have a highly inducible thermogenic capacity upon stimulation (16). Igniting white AT browning has become an attractive strategy for the treatment of obesity and its related metabolic disorders (17).
The silent information regulator 2 (Sir2) family of histone/protein deacetylases (Sirtuins) comprise homologs found across all kingdoms of life (18). There are seven Sirtuin homologs in humans, SIRT1–SIRT7. Sirtuins share significant sequence homology, contain conserved catalytic and nicotinamide adenine dinucleotide (NAD+)-binding domains, and regulate multiple cellular processes, including cell survival, senescence, and metabolic homeostasis (19). Sirtuins differ in their subcellular localization and substrate specificities. Mounting evidence indicated that Sirtuins are essential regulators of multiple processes in obesity-associated AT remodeling (20–23). Herein, we systematically summarized the roles of Sirtuins in regulating adipocyte fate, lipid mobilization, AT inflammation, AT fibrosis, and browning of AT (Table 1). The purpose of the current review is to provide insight into AT remodeling and inspire Sirtuins as therapeutic targets for obesity-associated metabolic disorders.
Table 1 Overview of the role of Sirtuins in adipose tissue remodeling.
NAD+ in adipose tissue
As the rate-limiting co-substrate of Sirtuins, NAD+ is important to regulate the functions of Sirtuins and, consequently, AT remodeling. Emerging evidence has revealed that NAD+ biology in AT is associated with metabolic flexibility in mice and humans (82–84). NAD+ levels in white AT are decreased in obesity, which is consistent with the activity of Sirtuins (85, 86). Similarly, long-term HFD feeding reduced the content of NAD+ in epididymal white AT, inguinal white AT, and interscapular brown AT, while long-term calorie restriction (CR) showed the opposite effects; in addition, NAD+ content in both white and brown AT was negatively associated with the cholesterol and TNF-α levels in plasma but positively correlated with adiponectin level in plasma (87). Enhancing NAD+ synthesis in the salvage pathway plays a critical role in the differentiation of 3T3-L1 preadipocytes (88). Nicotinamide phosphoribosyltransferase (NAMPT) functions intracellularly to catalyze the rate-limiting step of the NAD+ salvage pathway, which is the main source of NAD+ in AT (83). Loss of NAMPT impairs metabolic pathways involved in inflammation (84) and decreases adrenergic-mediated lipolysis in white AT (82). Adipocyte-specific NAMPT deletion causes local AT inflammation, but not systemic inflammation (89). Nicotinamide riboside (NR) was recently identified as a NAD+ precursor; NR supplementation increases NAD+ levels and activates SIRT1 and SIRT3, ultimately enhancing oxidative metabolism in brown AT and protecting from metabolic abnormalities in HFD-fed mice (90). Additionally, NR supplementation prevents the development of inflammation and fibrosis in white AT of old, but not young, female HFD-induced-obesity mice (91). These findings demonstrated the importance of NAD+ biology in AT remodeling. Further studies are needed to clarify the source and functions of NAD+ in AT.
Sirtuins in adipose tissue
SIRT1, existing primarily in the nucleus and partially in the cytoplasm, exhibits a deacetylase activity of histones and non-histone substrates, which manipulates multiple physiological processes in AT, including inflammatory responses, mitochondrial biogenesis, cellular senescence, and apoptosis/autophagy (92). SIRT2, originally identified as a tubulin deacetylase, is shuttled between the cytoplasm and the nucleus (93). SIRT2 participates in the regulation of adipocyte differentiation, gluconeogenesis, insulin action, and inflammatory responses by deacetylating various substrates (94). SIRT3, preferentially localized in mitochondria (95), possesses regulatory roles in multiple metabolic processes, including acetate metabolism and thermogenesis, by controlling mitochondrial biogenesis and function (96). SIRT3, rather than SIRT4 or SIRT5, is responsible for the overall protein deacetylation in mitochondria (97). SIRT4 and SIRT5 exist predominantly in mitochondria, whereas SIRT6 and SIRT7 are principally found in the nucleus.
The expression of Sirtuins in AT has been widely investigated, while the outcomes were controversial. The expression levels of SIRT2, SIRT4, and SIRT6 are comparable in white and brown AT, SIRT1 and SIRT7 maintain higher expression in white AT, and SIRT3 and SIRT5 are preferentially expressed in brown AT versus white AT (98). Compared with that of normal-weight individuals, the mRNA level of SIRT1 is lower and that of SIRT7 is higher in visceral and subcutaneous ATs from obese humans, while the expression of the other five Sirtuins is not related to body mass index (BMI) (99). In addition, the level of SIRT1 was found to be negatively correlated with BMI and AT macrophage infiltration in humans (100). The expression of SIRT1, SIRT3, and SIRT6 in subcutaneous AT was upregulated during weight loss (101). Consistently, the expression of SIRT1, SIRT3, and SIRT5 in subcutaneous AT is lower in the heavier co-twins of the BMI-discordant twin pairs (102). Another study showed that the mRNA expression of SIRT1, SIRT3, and SIRT7 is lower in subcutaneous AT of healthy obese subjects than that of lean subjects (86). Interestingly, overweight subjects showed lower SIRT3 and SIRT6 mRNA levels than normal-weight subjects; no differences in SIRT1 or SIRT6 levels were observed between obese and overweight subjects; the obesity group exhibited the highest expression, while overweight subjects showed the lowest expression of SIRT2 (103). The SIRT3 expression is relatively high at the initial stage of adipocyte differentiation and declines 4 days after hormonal stimulation in 3T3-L1 adipocytes (60). Inhibition of SIRT5 promoted the expression of SIRT6 in the differentiation process of bovine preadipocytes (71). Taken together, the expression profiles of Sirtuins and their functions in different physiologic contexts of AT vary, which in turn affect adipose tissue functions, and the change patterns are complicated and worthy of further exploration.
Diet and environmental stresses have been reported to target Sirtuins, as well as some small molecules. HFD feeding decreases the expression levels of SIRT1–4 and SIRT6 and increases the expression of SIRT5 in AT (104). Long-term CR increases the levels of SIRT1 (105, 106), SIRT2 (107), SIRT3 (98), and SIRT6 (108, 109) in AT but represses the level of SIRT4 (110). In addition, one report suggested no change of SIRT7 expression in white AT after short-term CR (111). Additionally, cold exposure upregulates the expression of SIRT1 (112), SIRT2 (55), SIRT3 (98), SIRT5 (22), and SIRT6 (75) in brown AT. It remains unclear how CR affects SIRT5 expression in AT and how cold exposure regulates SIRT4 and SIRT7 in AT.
Sirtuins in manipulating adipocyte fate
During obesity, white AT expands excessively by increasing the size of pre-existing adipocytes or generating new adipocytes from precursor cells. The process of preadipocyte differentiation into mature adipocyte is termed adipogenesis. It is worth noting that adipocyte expansion via adipogenesis can offset the negative metabolic effects of obesity, and increasing reports are focused on exploring the mechanisms and regulators of this adaptation process (113). Among them, Sirtuins have attracted more and more attention.
SIRT1–3 and SIRT7
Peroxisome proliferator-activated receptor γ (PPARγ) is one of the master regulators of adipocyte differentiation and is closely related to the development of obesity (24). Under fasting conditions, SIRT1 is activated to promote CDK2-associated cullin 1 (CACUL1) binding to PPARγ-responsive site without affecting CACUL1 expression, in turn repressing the transcriptional activity and adipogenic potential of PPARγ in 3T3-L1 cells (24). It has been reported that ECM in AT accelerates early adipogenesis, and SIRT1 mediates proadipogenic events triggered by ECM in subcutaneous AT (25). Conversely, SIRT7 promotes adipogenesis in mice by inhibiting the autocatalytic activation of SIRT1 (81). Strikingly, another report suggested that SIRT1 plays a positive role in the early stage of mouse embryonic stem cell (mESC) differentiation to adipocyte and exhibits a negative effect on the late stage of adipogenesis (50). SIRT1 deficiency increases the acetylation of nuclear receptor corepressor 1 (NCOR1) to inhibit adipogenesis; thus, SIRT1 plays a positive role during the early stage of mESCs to adipocyte differentiation (50).
In AT-derived mesenchymal stem cells (AT-MSCs), SIRT1 activated beige adipocyte differentiation in elderly AT-MSC via p53/p21 pathway, but not SIRT3 (52). On the contrary, another study indicated that the effects of SIRT1 on brown AT are not related to the differentiation process of brown adipocytes (29). The expression patterns of SIRT3 are correlated with brown adipocyte differentiation, and SIRT3 directly deacetylates PPAR coactivator-1α (PGC-1α) to promote the differentiation of fully thermogenic competent brown adipocytes (59). Depletion of SIRT3 decreases the protein level of forkhead box O 3a (FOXO3a) and subsequently impairs the ability of AT-derived human MSCs to undergo adipogenic differentiation, resulting in adipocyte dysfunction and IR (63).
It is worth noting that SIRT2 inhibits adipocyte differentiation. Apparently, the effects of SIRT1 and SIRT2 are similar in adipogenesis. Overexpression of SIRT1 and SIRT2 reduced lipid droplet number, attenuated lipid accumulation and adipocyte conversion, and prevented the proper induction of adipogenic markers, including PPARγ2 and CCAAT/enhancer-binding protein α (C/EBPα), in visceral AT-derived stem cells. Thus, the decreased expression of SIRT1 and SIRT2 promotes the differentiation capacity of visceral AT stem cells from obese humans, which is associated with fostering visceral AT expansion (26). SIRT2 directly deacetylates FOXO1 to affect FOXO1 acetylation/phosphorylation, increase its nuclear translocation, and suppresses adipogenesis (56). Moreover, SIRT2 promotes FOXO1 binding to PPARγ and subsequently inhibits its transcriptional activity to suppress adipogenesis (55).
SIRT4–6
In bovine AT, SIRT4 interacts coordinately with the transcription factors, including E2F transcription factor-1 (E2F-1), C/EBPβ, and homeobox A5 (HOXA5), to promote adipocyte differentiation (65). SIRT4 promotes branched-chain amino acid catabolism through methylcrotonyl-CoA carboxylase 1 (MCC1), resulting in the greatest enhancement of adipogenesis, and SIRT5 only modestly promotes adipogenesis, but not SIRT3 (64).
A recent study reported that SIRT5 inhibition stimulates brown-like adipogenesis in 3T3-L1 preadipocytes (67). SIRT5 inhibits the differentiation of bovine preadipocytes and simultaneously inhibits lipid synthesis and lipid deposition in adipocytes by activating the adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) and repressing the mitogen-activated protein kinase (MAPK) (68). Similarly, SIRT6 inhibits preadipocyte differentiation and synergizes with SIRT5 to reduce lipid deposition in preadipocytes through the activation of the AMPKα pathway (71). On the contrary, another study showed that SIRT6 promotes mitotic clonal expansion during adipogenesis by inhibiting the expression of kinesin family member C (KIFC) and enhancing casein kinase 2 (CK2) activity, while SIRT6 deficiency leads to a severe adipogenesis defect and reduced expression of adipogenic markers, including PPARγ, C/EBPα, adipocyte protein2 (aP2), and adiponectin (79).
In summary, SIRT1 regulates adipogenesis either positively or negatively, which depends on the stage of adipocyte differentiation, whereas SIRT7 promotes adipogenesis by inhibiting the autocatalytic activation of SIRT1 (Figure 1). SIRT2 exerts an inhibitory effect on adipogenesis by deacetylating FOXO1. SIRT3 and SIRT4 promote adipogenesis, while SIRT5 and SIRT6 impair preadipocyte differentiation and lipid deposition. Manipulation of the activity of SIRT1–6 might be a promising strategy to control adipocyte fate.
Figure 1 The roles of Sirtuins in regulating adipocyte differentiation. PPARγ and C/EBPα are the master regulators of preadipocyte commitment and terminal differentiation. FOXO plays an important role in the integration of hormone-activated signaling pathways with the complex transcriptional cascade that promotes adipocyte differentiation. PPARγ, peroxisome proliferator-activated receptor γ; FOXO, forkhead box O.
Sirtuins in regulating lipid mobilization
Obesity is characterized by the pathological expansion and dysfunction of AT. Lipogenesis is a process of the synthesis of fatty acids from non-lipid precursors. Lipolysis is a process of breaking down long-chain fatty acids to produce acetyl-CoA, which provides energetic needs for cells under physiological circumstances. Lipid mobilization, comprising lipogenesis and lipolysis, is critical for energy homeostasis. Sirtuins have received significant attention for their important roles in lipid mobilization in AT (114).
SIRT1 and SIRT2
It was reported that upregulation of SIRT1 triggers lipolysis and loss of fat, including the hydrolysis of TGs and the release of free fatty acid (FFA), by repressing PPARγ (27). ATGL protein is considered the rate-limiting lipolytic enzyme since the rates of lipolysis are directly proportional to the levels of the ATGL protein. SIRT1 controls fat storage and mobilization, at least in part by regulating lipolysis in adipocytes via FOXO1-mediated expression of ATGL (28). Another study indicated that SIRT1 activates AMPK, which plays a crucial role in adipocyte lipolysis (20). Consistently, in white AT, SIRT1 knockdown not just fully recovered the resveratrol-elevated ATGL and positive regulatory domain containing 16 (PRDM16) protein but also reduced the resveratrol-elevated AMPK phosphorylation, suggesting that SIRT1 is the upstream factor of AMPK to control lipid metabolism (57).
SIRT2 increases lipolysis in mature adipocytes (55). SIRT2 mediates the increase in fatty acid oxidation (FAO) upon hypoxia-inducible factor-1α (HIF-1α) inactivation via PGC-1α, but not SIRT1 (58).
SIRT3 and SIRT4
SIRT3 is able to prevent the loss of brown AT during obesity and metabolic disorders. Knockout of SIRT3 obviously promoted lipid droplet accumulation in brown AT (21). Interestingly, SIRT3 plays a minimal role in AT mitochondrial biology and systemic metabolism in adipocytes from SIRT3 knockout mice. Loss of SIRT3 in adipocytes showed no obvious change in metabolic responses to HFD feeding and aging (115). Overexpression of SIRT3 activated macroautophagy in mature adipocytes by activating the AMPK–unc-51-like kinase 1 (ULK1) pathway, which in turn resulted in smaller lipid droplet size and reduced lipid accumulation (60).
HFD feeding increases SIRT4 levels in mice (116), while in nutrient-replete conditions, SIRT4 is active to repress FAO by deacetylating malonyl CoA decarboxylase (MCD), an enzyme that produces acetyl-CoA from malonyl-CoA and stimulates lipogenesis (66).
SIRT5 and SIRT6
SIRT5 deficiency impairs FAO, glutamate dehydrogenase (GDH) activity, and metabolic flexibility in brown adipocytes (69). In addition, a recent study reported that SIRT5 deficiency stimulates brown adipogenesis and ATGL function, which reduces intracellular lipid storage by promoting lipolysis and ultimately affects brown AT function (67). Strikingly, one study reported that SIRT5 deficiency did not cause any significant metabolic abnormalities under either chow or HFD conditions (70). Consistently, another study suggested there were no differences in the expression of genes related to fatty acid synthesis or transport, lipolysis, mitochondrial oxidative phosphorylation, or glucose transport in brown AT-specific SIRT5 knockout mice under standard housing conditions (22°C, normal chow diet) (69). Contradictory results might be due to different experimental subjects and conditions. Therefore, more studies are needed to confirm the effects of SIRT5 on lipid mobilization.
SIRT6 overexpression is associated with the downregulation of a selective group of PPAR-responsive genes and genes associated with lipid storage, including angiopoietin-like protein 4 (ANGPTL4), adipocyte fatty acid-binding protein (FABP4 or aP2), and diacylglycerol acyltransferase 1 (DGAT) (72). Fat-specific SIRT6 knockout sensitized mice to HFD-induced obesity, which was attributed to adipocyte hypertrophy instead of adipocyte hyperplasia by decreasing expression of ATGL. Furthermore, SIRT6 deficiency suppresses the expression of ATGL by regulating FOXO1 acetylation and subcellular localization, thereby inhibiting lipolytic activity (73).
In conclusion, SIRT1 triggers lipolysis by repressing PPARγ, activating AMPK, and increasing the expression of ATGL. SIRT2 mediates the increase in FAO via PGC-1α. SIRT3 reduces lipid droplet size and lipid accumulation by activating the AMPK-ULK1 pathway. SIRT4 represses FAO by deacetylating MCD. The role of SIRT5 in lipid mobilization is controversial and needs further investigation. SIRT6 deficiency leads to decreased lipolytic activity by increasing phosphorylation and acetylation of FOXO1. In contrast, little is known about SIRT7 in lipid mobilization (Figure 2). Understanding the roles of Sirtuins in lipid mobilization would likely provide key insights into developing therapeutics against obesity and obesity-induced metabolic disease.
Figure 2 The roles of SIRT1-SIRT6 in manipulating lipid mobilization. Lipid mobilization is comprised of lipogenesis and lipolysis. Large lipid droplets are separated into small ones to initial lipolysis. TGs stored in lipid droplets are mobilized by the hydrolytic action of the three main lipases of the adipocyte to release FFAs, which are broken down to produce energy through FAO. TGs, triglycerides; FFAs, free fatty acids; FAO, fatty acid oxidation.
Sirtuins in controlling adipose tissue inflammation
Elevating evidence suggests that the sequential course of inflammation is linked with immune responses, energy metabolism, and insulin sensitivity, which are regulated by Sirtuins (117). The roles of Sirtuins in acute/chronic inflammation have been summarized previously (117–119). AT is generally considered to be an active endocrine organ and takes a pivotal role in systemic energy homeostasis. AT inflammation, characterized by augmented infiltration and altered polarization of macrophages, results in IR and its associated metabolic diseases (15). In human stem cells from subcutaneous and visceral fat depots, the levels of Sirtuins 1-7 are involved in obesity-associated inflammation, as well as the interplay with PPARδ (120). Herein, the roles of Sirtuins in manipulating AT inflammation were summarized.
SIRT1
SIRT1 has been reported to alleviate inflammation in a variety of tissues and cells (93). SIRT1 in AT plays a protective role against inflammation through multiple mechanisms. Macrophage infiltration and the gene expression of inflammatory cytokines were elevated in the heterozygous SIRT1 knockout mice fed with a moderate-fat diet (30). AT macrophages surround and ingest dying or dead adipocytes to form crown-like structures (CLSs). Myeloid SIRT1 deficiency promotes massive macrophage infiltration in AT and increases the number of CLSs (31, 32). Myeloid SIRT1 regulates pro-inflammatory cytokines and macrophage infiltration in AT from HFD mice (32). In addition, mice with AT-selective overexpression of human SIRT1 (H363Y), a dominant-negative mutant that inhibits endogenous SIRT1 activity, exhibited elevating inflammation (33). AT-specific-SIRT1 (H363Y) overexpressed mice exhibits hyperglycemia, dyslipidemia, and ectopic lipid deposition at a much younger age than their wild-type littermates (33). However, the pro-inflammatory effect of HFD is the triggering signal of SIRT1 cleavage.
In general, SIRT1 regulates both pro-inflammatory and anti-inflammatory cytokines. The pro-inflammatory signals that activate caspase-1 through the nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome, such as TNF-α, cause the cracking of SIRT1. Indeed, AT-specific SIRT1 knockout mice obviously develop IR (34). In visceral AT, a negative correlation between the mRNA level of SIRT1 and IL-1β was observed (35). In addition, SIRT1 blocks the infiltration of macrophages and promotes the polarization toward anti-inflammatory M2 macrophages, which in turn ameliorates inflammation in AT (46); concomitantly, SIRT1 deacetylates the transcription factor NFATc1, thereby enhancing the binding of NFATc1 to the IL-4 gene promoter and finally modulating macrophage polarization (53).
Nuclear factor-κB (NF-κB) acts as a key regulator of inflammation to induce pro-inflammatory cytokines, which in turn increase adiposity and AT dysfunction (121). SIRT1 acts as a negative regulator of the inflammatory pathway and a positive regulator of insulin signaling in adipocytes by deacetylating NF-κB and inhibiting binding to the promoter of its target genes (36–40). Consistently, SIRT1 knockdown in white AT leads to NF-κB nuclear translocation by reducing histone H3 lysine 9 (H3K9) deacetylation (122). Interestingly, loss of SIRT1 leads to compensatory SIRT6 deacetylase activity on H3K9, demonstrating that SIRT1 and SIRT6 act on NF-κB through different mechanisms (40). Moderate SIRT1 overexpression ameliorates the effects of LPS on brown AT inflammation by the reduced acetylation of NF-κB, STAT3, and p38 MAPK (29, 39, 123). It is generally believed that the cluster of differentiation 40 (CD40)/CD40 ligand (CD40L) pathway is an integral part of the onset and maintenance of inflammatory reactions in obesity. SIRT1 modulates TNF-α-induced expression of CD40 partially via the NF-κB pathway in 3T3-L1 adipocytes (41). SIRT1 is a key upstream regulator in AT inflammation, by controlling the gain of pro-inflammatory transcription in response to inducers including fatty acids, hypoxia, and endoplasmic reticulum stress. The activation of SIRT1 by small molecules reduces the inflammatory response induced by FFA in macrophages and alleviates inflammation in white AT (38). SIRT1 suppresses NF-κB signaling pathway, which might provide another way to maintain AMPK activity against inflammatory challenges (42).
Phosphorylation of protein kinase B (Akt) activates the mammalian target of rapamycin (mTOR) signal in macrophages and then triggers inflammation and IR in obese mice (124). SIRT1 interacts with Akt2 and inhibits the mTOR/S6K1 pathway to attenuate AT inflammation in mice (43). Adiponectin, an adipocyte-derived relaxation factor with anti-inflammatory activity, promotes nitric oxide production in the endothelium. SIRT1 upregulates adiponectin mRNA expression in 3T3-L1 adipocytes via a FOXO1-C/EBPα transcriptional complex (44). SIRT1 improves the release of adiponectin from perivascular AT to fight against inflammatory insult (42).
Strikingly, adipocyte-specific deletion of SIRT1 exacerbates the detrimental effects of acute HFD feeding but shows protective effects in the context of chronic HFD exposure. Consistent with the more glucose tolerant and less insulin state of the adipocyte-specific SIRT1 knockout mice after chronic HFD, these mice possessed lower circulating levels of MCP-1 and TNF-α but increased levels of IL-10 and arginase in epididymal AT, which were mediated through hyperacetylation and dephosphorylation of PPARγ Ser273 along with reduced CDK5 activity. Additionally, increased p65 acetylation (NF-κB) was detected in these mice. Therefore, in the case of chronic HFD-induced obesity, inhibition of SIRT1 in adipocytes might result in improved metabolic functions (45). During the onset of obesity, SIRT1 deficiency in adipocytes (rather than myelocytes) accelerates peripheral IR by regulating macrophage infiltration and polarization, which has nothing to do with obesity (53).
Most studies have shown that SIRT1 plays a protective role in AT inflammation, but there are still very few studies with the opposite observation. The types of diet and the stage of obesity could affect the roles of SIRT1 in AT inflammation. Therefore, more studies are needed to further confirm the roles of SIRT1 in AT inflammation in the future.
SIRT3 and SIRT6
The roles of other Sirtuins in AT inflammation have been seldom studied. SIRT3 mediates a metabolic switch in macrophages by deacetylating pyruvate dehydrogenase E1α (PDHA1) lysine, which in turn promotes NLRP3 inflammasome activation (61). Jun N-terminal kinase (JNK) in macrophages contributes to the accumulation of macrophages and plays a key role in the metabolic response to obesity, including IR (125). SIRT6 deficiency causes elevated inflammation in AT of mice by increasing the occupancy of c-Jun, downstream of JNK, on the gene promoters of IL-6 and MCP-1 (73). Another study suggested that SIRT6 regulates at least two stages of adipose inflammation: augmenting the migration potential of macrophages toward AT-derived chemoattractants and facilitating pro-inflammatory M1 polarization; SIRT6 deletion in macrophages promotes the activation of NF-κB and production of IL-6, resulting in STAT3 activation and the positive feedback circuits for NF-κB stimulation (74). Furthermore, adipocyte SIRT6 drives macrophage polarization toward M2 by increasing the production of the canonical type 2 cytokine IL-4 by adipocytes in a cell autonomous manner, which in turn attenuates pro-inflammatory responses in AT (80). Consistently, adipocyte SIRT6 decreases the M1 composition in white AT, and SIRT6 deficiency in adipocytes leads to an aggravating inflammatory reaction in white AT (23). Eosinophils secrete Th2 cytokine IL-4/IL-13 promoting M2 macrophage polarization. Myeloid-specific SIRT6 deficiency affects both eosinophils and M2 macrophage content in subcutaneous AT upon cold exposure, confirming a close link between eosinophils and M2 macrophages (76).
Taken together, SIRT1, SIRT3, and SIRT6 participate in the regulation of AT inflammation, while other Sirtuins remain poorly understood and need further researches (Figure 3).
Figure 3 SIRT1, SIRT3, and SIRT6 participate in the regulation of AT inflammation via different pathways. AT inflammation is initiated and sustained over time by dysfunctional adipocytes that secrete inflammatory adipokines and by infiltration of bone marrow-derived monocytes that signal via production of cytokines and chemokines. White AT is the major source of obesity-related inflammation; in turn, AT inflammation leads to IR and metabolic dysfunction. AT, adipose tissue; IR, insulin resistance.
Sirtuins in manipulating adipose tissue fibrosis
ECM, a basic component of the specialized adipose niche, provides architectural elements and non-structural molecules that affect progenitor cells and regulate the expandability of AT (25). Fibrosis consists of excessive deposition of ECM, which eventually leads to organ failure and death in several chronic diseases (126). The important roles of Sirtuins in regulating AT fibrotic response have been gradually revealed.
SIRT1
SIRT1 modulates fatty acid metabolism and lipid mobilization in adipocytes via modification of the extracellular environment. Small adipocytes, less ECM between adipocytes, and reduced macrophage infiltration in AT were observed in SIRT1 null animals (46). Consistently, SIRT1 deficiency suppresses the expression of leptin, adiponectin, and matrix metalloproteinases 3/13 (MMP3/13) and elevates the expression of the pro-fibrotic collagen (Collagen 6A3) in adipocytes. Pathway analysis revealed SIRT1-dependent key transcription factors, including PPARα, sterol regulatory element-binding transcription factor 1/2 (SREBF1/2), and PGC-1α (51). Moreover, SIRT1 overexpression downregulates the genes related to ECM remodeling (i.e., collagens, metalloproteases, and integrins) accompanied by a lower degree of inflammation-related fibrosis in visceral AT (39).
SIRT3
Upon Angiotensin (Ang) II stimulation, adipocytes adjacent to the adventitia enlarge, while collagen IV deposition in perivascular AT increases. Myeloid SIRT3 deficiency resulted in severe loss of brown AT characteristics and increased expression of collagen VI, which ultimately aggravated Ang II-induced perivascular AT dysfunction (61).
SIRT1 participates in the regulation of AT fibrosis by controlling collagens and metalloproteases. The roles of other Sirtuins in AT fibrosis are seldom studied.
Sirtuins in controlling adipose tissue browning
Browning of white AT is characterized by the induction of beige adipocytes, endowing brown AT-like characteristics onto white AT, and remodeling it to energy processing capacity in addition to energy storage capacity (54). AT browning plays a crucial role in energy metabolism, which could be a potential therapeutic strategy against obesity and metabolic syndrome.
SIRT1
Pro-opiomelanocortin (POMC) neurons selectively regulate brown AT-like remodeling of perigonadal white AT, and SIRT1 deficiency affects the survival of POMC neurons (47). SIRT1 promotes AT browning in mice via the deacetylation of PPARγ on Lys268 and Lys293, which in turn recruits the transcriptional coactivator PRDM16 to PPARγ, resulting in selective induction of brown AT genes and repression of white AT genes (27, 48). It has been reported that SIRT1 regulates angiogenesis by modulating angiogenic factors (such as vascular endothelial growth factor, platelet-derived growth factor, and transforming growth factor-β), which in turn controls AT function (46). PGC-1α, highly expressed in brown AT, is a key factor of brown fat thermogenesis and white AT browning (20, 75). SIRT1 deficiency displays a lower thermogenic activity and a significant decrease of UCP1 and PGC-1α expression in brown AT from HFD-fed mice, which are accompanied by aggravated mitochondrial dysfunction. In line with this, oxidation genes were downregulated, including PPARα, peroxisomal acyl-coenzyme A oxidase (ACOX), and carnitine palmitoyltransferase 1b (CPT1b), and the mitochondria content was lower, ultimately leading to brown AT degeneration (54). Furthermore, SIRT1 is an endogenous activator of FGF21 in hepatocytes, which in turn systemically controls white AT browning and energy homeostasis (49). Another study reported that SIRT1 induces white AT browning following sleeve gastrectomy by activating AMPK (20).
SIRT3
SIRT3 deletion aggravates brown-to-white adipocyte conversion induced by high salt via inhibiting mitochondrial biogenesis and perilipin-1 expression; however, restoring SIRT3 prevents high salt-induced brown AT to white AT conversion by improving mitochondrial respiration (62). Consistently, knockout of SIRT3 promotes the accumulation of lipid droplets in brown AT and blocks the inhibitory effect of capsaicin on HFD-induced brown AT whitening (21). Myeloid SIRT3 deficiency reduces UCP1 and perilipin-1 protein levels and promotes collagen IV deposition in brown AT, which in turn exacerbates perivascular AT remodeling and AT dysfunction (61).
SIRT5
SIRT5 deficiency in mice resulted in less browning capacity in subcutaneous AT and a slight imbalance in energy and glucose homeostasis, which might be related to the inhibition of isocitrate dehydrogenase (IDH) activity and reduction of α-ketoglutarate concentration (22). In inguinal AT from SIRT5 knockout mice, the expression of thermogenic genes including UCP1, cell death-inducing DFFA-like effector a (CIDEA) and cytochrome c oxidase subunit 7A1 (COX7A1), and FAO genes, including CPT1b and medium-chain acyl-coenzyme A dehydrogenase (MCAD), was downregulated, while the expression of adipogenic genes (PPARγ and C/EBPα) was not changed (22). Another report suggested that mice lacking SIRT5 in brown AT showed difficulty converting fuel from FFA to glucose after overnight fasting. Strikingly, there was no difference in the expression of genes related to browning in brown AT-specific SIRT5 knockout mice (69).
SIRT6
SIRT6 regulates AT browning in response to either cold exposure or β-adrenergic agonist (75). Similarly, SIRT6 deficiency in POMC neurons impairs the browning and lipolytic functions of AT in HFD-fed mice by modulating leptin signaling (77). Additionally, SIRT6 deficiency in mice resulted in impaired AT browning and reduced expression of UCP1, accompanied by downregulation of p38 MAPK/ATF2 signaling (23). SIRT6 deficiency leads to impairment of thermogenesis and browning by decreasing UCP1 and PGC-1α in subcutaneous white AT of myeloid SIRT6 knockout mice (76). SIRT6-deficient mice showed a significant increase in glucose uptake in brown AT, and HIF-1α is required to recruit SIRT6 to glycolytic gene promoters (78).
Taken together, emerging evidence has demonstrated that the Sirtuin family plays crucial roles in AT browning, comprehensively contributing to metabolic functions (Figure 4).
Figure 4 The roles of SIRT1, SIRT3, SIRT5, and SIRT6 in controlling AT browning. AT browning is a promising anti-obese strategy to enhance energy expenditure through heat production. Sirtuins widely participate in beige cell differentiation and function. AT, adipose tissue.
Clinical progresses of Sirtuins
As Sirtuins are potential therapeutic targets for metabolic diseases, considerable efforts have been paid to develop specific Sirtuin activators and inhibitors in recent years. Unfortunately, there is still no drug approved for clinical use. Till now, one selective SIRT1 inhibitor, selisistat (also known as Ex-527 or SEN0014196), and several small-molecule SIRT1 activators have been evaluated in clinical trials (127). Data on Sirtuin activators and inhibitors are still limited, and their therapeutic efficacy remains under investigation. Considering Sirtuins are involved in multiple signaling pathways, the side effects of Sirtuin activators and inhibitors should be paid attention to in clinical trials. Here, we summarized the application of Sirtuin activators and inhibitors on obesity-related metabolic diseases.
Inhibitor of Sirtuins
Selisistat, a selective SIRT1 inhibitor, was shown to be safe (128) and well tolerated in healthy volunteers and Huntington’s disease (HD) patients in short-term studies (129). Strikingly, a study showed that administration of selisistat over 14 days showed no pro-inflammatory effects (129), although some pre-clinical studies suggested its pro-inflammatory effect.
Activators of Sirtuins
Resveratrol was identified as the most potent SIRT1 activator (130). One study showed that 150 mg/day trans-resveratrol (99.9%) supplementation in obese subjects for 30 days decreased the expression levels of inflammation-related genes, plasma levels of several inflammatory markers, and leukocyte numbers, and reduced AT lipolysis (131). However, resveratrol supplementation (75 mg/day) in non-obese, postmenopausal women with normal glucose tolerance did not change body composition, resting metabolic rate, plasma lipids, or inflammatory markers (132). Longevinex is a modified form of resveratrol; it had no effect on insulin sensitivity or the inflammation markers (IL-6) in 34 patients diagnosed with metabolic syndrome (133).
Because resveratrol suffered from low bioavailability and potency, as well as low target specificity, synthetic Sirtuin activators are emerging, such as SRT501, SRT2104, SRT2379, and SRT3025 (127). SRT501 has entered phase III clinical trials for the treatment of type 2 diabetes, and the pharmacokinetics and safety study of SRT2379 evaluated in healthy male volunteers have been completed (130). The promising clinical data on SRT2104 revealed that small-molecule SIRT1 activators with good pharmacokinetics and tolerability profiles could provide important new therapeutic paradigms and be developed as candidates to treat inflammatory diseases (134, 135). There is still no Sirtuin activator or inhibitor approved for clinical use; further structural modifications, pharmacological evaluations, and clinical trials are needed.
Perspectives
Understanding the roles of Sirtuins in AT remodeling could help to untangle the comprehensive regulatory circuits of obesity. Each member of the Sirtuin family participates in the regulation of adipogenesis, lipid mobilization, AT inflammation, AT fibrosis, and AT browning through multiple pathways. Among them, SIRT1 has been widely investigated with multiple functions in AT remodeling. Specifically, SIRT1 suppresses adipogenesis by modifying the activity of PPARγ in preadipocyte and white AT; triggers lipolysis by repressing PPARγ and activating the AMPK pathway; exerts anti-inflammatory effect by repressing NF-κB, NLRP3, and mTOR pathways; and regulates ECM deposition and AT fibrosis. SIRT3 not only promotes brown adipocyte differentiation but also stimulates thermogenesis. SIRT3 reduces lipid droplet size and lipid accumulation by activating the AMPK pathway and mediates NLRP3 inflammasome activation to exhibit an anti-inflammatory effect. SIRT6 suppresses preadipocyte differentiation and lipid deposition through the activation of the AMPK pathway. However, the roles of other Sirtuins in AT remain poorly understood. Adipocyte-, leukocyte-, or myeloid-specific knockout or knockin animal models are powerful tools to investigate the physiological function of Sirtuin deacetylases and their possible cross-regulation in AT remodeling. It should be noted that the pathway of Sirtuins and the interaction between Sirtuins vary greatly in different models, which need further exploration. Since the functions of Sirtuins are related to the stage of adipocyte differentiation, cell types (preadipocytes, white adipocytes, brown adipocytes, or beige adipocyte), and tissues (white or brown AT), the studies about Sirtuins on AT remodeling should be more comprehensive. Sirtuins mainly play protective roles in AT remodeling, while the effects of Sirtuin inhibitors and activators on obesity and obesity-related metabolic diseases remain elusive.
In summary, AT remodeling is a series of physiological and pathological responses of AT under the challenge of positive energy. By regulating AT remodeling, Sirtuin deacetylases could revolutionize obesity and its related complications. This review may contribute to a better understanding of AT remodeling in obesity and the possible development of Sirtuins as new therapeutic targets.
Author contributions
All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by JC and RL. The first draft of the manuscript was written by JC, and all authors reviewed subsequent drafts and have approved the final version for submission. All authors contributed to the article and approved the submitted version.
Funding
Financial support by the Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China (2022ZYXK2011007), National Natural Science Foundation of China (81872754, 82073715), the Research Fund of University of Macau (MYRG2020-00091-ICMS), Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau (QRCM-IRG2022-014), and the Science and Technology Development Fund, Macao SAR (FDCT 0064/2021/AGJ), is gratefully acknowledged.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction. Circ Res (2021) 128(7):951–68. doi: 10.1161/CIRCRESAHA.121.318093
2. Khwatenge CN, Pate M, Miller LC, Sang Y. Immunometabolic dysregulation at the intersection of obesity and COVID-19. Front Immunol (2021) 12:732913. doi: 10.3389/fimmu.2021.732913
3. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest (2019) 129(10):3978–89. doi: 10.1172/JCI129186
4. Lin K, Yang N, Luo W, Qian JF, Zhu WW, Ye SJ, et al. Direct cardio-protection of dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling. Acta Pharmacol Sin (2022) 43(10):2624–35. doi: 10.1038/s41401-022-00885-8
5. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose tissue remodeling: Its role in energy metabolism and metabolic disorders. Front Endocrinol (2016) 7:30. doi: 10.3389/fendo.2016.00030
6. Bilal M, Nawaz A, Kado T, Aslam MR, Igarashi Y, Nishimura A, et al. Fate of adipocyte progenitors during adipogenesis in mice fed a high-fat diet. Mol Metab (2021) 54:101328. doi: 10.1016/j.molmet.2021.101328
7. Pyrina I, Chung KJ, Michailidou Z, Koutsilieris M, Chavakis T, Chatzigeorgiou A. Fate of adipose progenitor cells in obesity-related chronic inflammation. Front Cell Dev Biol (2020) 8:644. doi: 10.3389/fcell.2020.00644
8. Grabner GF, Xie H, Schweiger M, Zechner R. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nat Metab (2021) 3(11):1445–65. doi: 10.1038/s42255-021-00493-6
9. Ting L, Allison N, Jessica F, Alex S, Xianliang R, Bingbing J, et al. AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes (2016) 65(8):2295–310. doi: 10.2337/db15-1122/-/DC1
10. Marcelin G, Silveira ALM, Martins LB, Ferreira AV, Clement K. Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis. J Clin Invest (2019) 129(10):4032–40. doi: 10.1172/JCI129192
11. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol (2020) 10:1607. doi: 10.3389/fphys.2019.01607
12. Yao J, Wu D, Qiu Y. Adipose tissue macrophage in obesity-associated metabolic diseases. Front Immunol (2022) 13:977485. doi: 10.3389/fimmu.2022.977485
13. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab (2014) 20(1):103–18. doi: 10.1016/j.cmet.2014.05.005
14. Li D, Zhang T, Lu J, Peng C, Lin L. Natural constituents from food sources as therapeutic agents for obesity and metabolic diseases targeting adipose tissue inflammation. Crit Rev Food Sci Nutr (2021) 61(12):1947–65. doi: 10.1080/10408398.2020.1768044
15. Li C, Xu MM, Wang K, Adler AJ, Vella AT, Zhou B. Macrophage polarization and meta-inflammation. Transl Res (2018) 191:29–44. doi: 10.1016/j.trsl.2017.10.004
16. Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab (2020) 2(1):97–109. doi: 10.1038/s42255-019-0152-6
17. Liu J, Wang Y, Lin L. Small molecules for fat combustion: targeting obesity. Acta Pharm Sin B (2019) 9(2):220–36. doi: 10.1016/j.apsb.2018.09.007
18. Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab (2014) 25(3):138–45. doi: 10.1016/j.tem.2013.12.001
19. Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci (2009) 1173 Suppl:E10–9. doi: 10.1111/j.1749-6632.2009.04952.x
20. Liu L, Zhang T, Hu J, Ma R, He B, Wang M, et al. Adiponectin/SIRT1 axis induces white adipose browning after vertical sleeve gastrectomy of obese rats with type 2 diabetes. Obes Surg (2020) 30(4):1392–403. doi: 10.1007/s11695-019-04295-4
21. Gao P, Jiang Y, Wu H, Sun F, Li Y, He H, et al. Inhibition of mitochondrial calcium overload by SIRT3 prevents obesity- or age-related whitening of brown adipose tissue. Diabetes (2020) 69(2):165–80. doi: 10.2337/db19-0526
22. Shuai L, Zhang LN, Li BH, Tang CL, Wu LY, Li J, et al. SIRT5 regulates brown adipocyte differentiation and browning of subcutaneous white adipose tissue. Diabetes (2019) 68(7):1449–61. doi: 10.2337/db18-1103
23. Wu D, Bang IH, Park BH, Bae EJ. Loss of Sirt6 in adipocytes impairs the ability of adipose tissue to adapt to intermittent fasting. Exp Mol Med (2021) 53(9):1298–306. doi: 10.1038/s12276-021-00664-1
24. Jang MJ, Park UH, Kim JW, Choi H, Um SJ, Kim EJ. CACUL1 reciprocally regulates SIRT1 and LSD1 to repress PPARgamma and inhibit adipogenesis. Cell Death Dis (2017) 8(12):3201. doi: 10.1038/s41419-017-0070-z
25. Trivanovic D, Drvenica I, Kukolj T, Obradovic H, Okic Djordjevic I, Mojsilovic S, et al. Adipoinductive effect of extracellular matrix involves cytoskeleton changes and SIRT1 activity in adipose tissue stem/stromal cells. Artif Cells Nanomed Biotechnol (2018) 46(sup3):S370–S82. doi: 10.1080/21691401.2018.1494183
26. Perrini S, Porro S, Nigro P, Cignarelli A, Caccioppoli C, Genchi VA, et al. Reduced SIRT1 and SIRT2 expression promotes adipogenesis of human visceral adipose stem cells and associates with accumulation of visceral fat in human obesity. Int J Obes (2020) 44(2):307–19. doi: 10.1038/s41366-019-0436-7
27. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature (2004) 429(6993):771–6. doi: 10.1038/nature02583
28. Chakrabarti P, English T, Karki S, Qiang L, Tao R, Kim J, et al. SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J Lipid Res (2011) 52(9):1693–701. doi: 10.1194/jlr.M014647
29. Boutant M, Joffraud M, Kulkarni SS, Garcia-Casarrubios E, Garcia-Roves PM, Ratajczak J, et al. SIRT1 enhances glucose tolerance by potentiating brown adipose tissue function. Mol Metab (2015) 4(2):118–31. doi: 10.1016/j.molmet.2014.12.008
30. Xu F, Gao Z, Zhang J, Rivera CA, Yin J, Weng J, et al. Lack of SIRT1 (Mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology (2010) 151(6):2504–14. doi: 10.1210/en.2009-1013
31. Kim KE, Jeong EA, Lee JY, Yi CO, Park KA, Jin Z, et al. Myeloid sirtuin1 deficiency aggravates hippocampal inflammation in mice fed high-fat diets. Biochem Biophys Res Commun (2018) 499(4):1025–31. doi: 10.1016/j.bbrc.2018.04.044
32. Ka SO, Song MY, Bae EJ, Park BH. Myeloid SIRT1 regulates macrophage infiltration and insulin sensitivity in mice fed a high-fat diet. J Endocrinol (2015) 224(2):109–18. doi: 10.1530/JOE-14-0527
33. Xu C, Cai Y, Fan PC, Bai B, Chen J, Deng HB, et al. Calorie restriction prevents metabolic aging caused by abnormal SIRT1 function in adipose tissues. Diabetes (2015) 64:1576–90. doi: 10.2337/db14-1180/-/DC1
34. Chalkiadaki A, Guarente L. High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab (2012) 16(2):180–8. doi: 10.1016/j.cmet.2012.07.003
35. Song YS, Lee SK, Jang YJ, Park HS, Kim JH, Lee YJ, et al. Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract (2013) 101(3):341–8. doi: 10.1016/j.diabres.2013.07.002
36. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol (2009) 29(5):1363–74. doi: 10.1128/MCB.00705-08
37. Serrano-Marco L, Chacón MR, Maymó-Masip E, Barrosa E, Salvadó L, Wabitsch M, et al. TNF-alpha inhibits PPARbeta/delta activity and SIRT1 expression through NF-kappaB in human adipocytes. Biochim Biophys Acta (2012) 1821(9):1177–85. doi: 10.1016/j.bbalip.2012.05.006
38. Xiang DM, Song XZ, Zhou ZM, Liu Y, Dai XY, Huang XL, et al. Chronic kidney disease promotes chronic inflammation in visceral white adipose tissue. Am J Physiol Renal Physiol (2017) 312(4):F689–701. doi: 10.1152/ajprenal.00584.2016
39. Pardo R, Velilla M, Herrero L, Cervela L, Ribeiro ML, Simó R, et al. Calorie restriction and SIRT1 overexpression induce different gene expression profiles in white adipose tissue in association with metabolic improvement. Mol Nutr Food Res (2021) 65(9):2000672. doi: 10.1002/mnfr.202000672
40. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, Fessler MB, et al. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol Cell Biol (2010) 30(19):4712–21. doi: 10.1128/MCB.00657-10
41. Lin QQ, Yan CF, Lin R, Zhang JY, Wang WR, Yang LN, et al. SIRT1 regulates TNF-alpha-induced expression of CD40 in 3T3-L1 adipocytes via NF-kappaB pathway. Cytokine (2012) 60(2):447–55. doi: 10.1016/j.cyto.2012.05.025
42. Sun Y, Li J, Xiao N, Wang M, Kou J, Qi L, et al. Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1. Pharmacol Res (2014) 89:19–28. doi: 10.1016/j.phrs.2014.07.006
43. Liu Z, Gan L, Liu G, Chen Y, Wu T, Feng F, et al. Sirt1 decreased adipose inflammation by interacting with Akt2 and inhibiting mTOR/S6K1 pathway in mice. J Lipid Res (2016) 57(8):1373–81. doi: 10.1194/jlr.M063537
44. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-c/enhancer-binding protein alpha transcriptional complex. J Biol Chem (2006) 281(52):39915–24. doi: 10.1074/jbc.M607215200
45. Mayoral R, Osborn O, McNelis J, Johnson AM, Oh DY, Izquierdo CL, et al. Adipocyte SIRT1 knockout promotes PPARgamma activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol Metab (2015) 4(5):378–91. doi: 10.1016/j.molmet.2015.02.007
46. Xu F, Burk D, Gao Z, Yin J, Zhang X, Weng J, et al. Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice. Endocrinology (2012) 153(4):1706–16. doi: 10.1210/en.2011-1667
47. Ramadori G, Fujikawa T, Fukuda M, Anderson J, Morgan DA, Mostoslavsky R, et al. SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab (2010) 12(1):78–87. doi: 10.1016/j.cmet.2010.05.010
48. Qiang L, Wang L, Kon N, Zhao W, Lee S, Zhang Y, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of ppargamma. Cell (2012) 150(3):620–32. doi: 10.1016/j.cell.2012.06.027
49. Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology (2014) 146(2):539–49 e7. doi: 10.1053/j.gastro.2013.10.059
50. Jung YJ, Park W, Noh JM, Kang KP, Nguyen-Thanh T, Han MK, et al. SIRT1 induces the adipogenic differentiation of mouse embryonic stem cells by regulating RA-induced RAR expression via NCOR1 acetylation. Stem Cell Res (2020) 44:101771. doi: 10.1016/j.scr.2020.101771
51. Majeed Y, Halabi N, Madani AY, Engelke R, Bhagwat AM, Abdesselem H, et al. SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways. Sci Rep (2021) 11(1):8177. doi: 10.1038/s41598-021-87759-x
52. Khanh VC, Zulkifli AF, Tokunaga C, Yamashita T, Hiramatsu Y, Ohneda O. Aging impairs beige adipocyte differentiation of mesenchymal stem cells via the reduced expression of sirtuin 1. Biochem Biophys Res Commun (2018) 500(3):682–90. doi: 10.1016/j.bbrc.2018.04.136
53. Hui X, Zhang M, Gu P, Li K, Gao Y, Wu D, et al. Adipocyte SIRT1 controls systemic insulin sensitivity by modulating macrophages in adipose tissue. EMBO Rep (2017) 18(4):645–57. doi: 10.15252/embr.201643184
54. Xu F, Zheng X, Lin B, Liang H, Cai M, Cao H, et al. Diet-induced obesity and insulin resistance are associated with brown fat degeneration in SIRT1-deficient mice. Obesity (2016) 24(3):634–42. doi: 10.1002/oby.21393
55. Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma. Mol Biol Cell (2009) 20(3):801–8. doi: 10.1091/mbc.E08-06-0647
56. Jing E, Gesta S and CRK. Sirt2 regulates adipocyte differentiation involving FoxO1 Acetylation/Deacetylation. Cell Metab (2007) 6(2):105–14. doi: 10.1016/j.cmet.2007.07.003
57. Li Z, Zhang Z, Ke L, Sun Y, Li W, Feng X, et al. Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice. FASEB J (2020) 34(3):4527–39. doi: 10.1096/fj.201902222R
58. Krishnan J, Danzer C, Simka T, Ukropec J, Walter KM, Kumpf S, et al. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev (2012) 26(3):259–70. doi: 10.1101/gad.180406.111
59. Giralt A, Hondares E, Villena JA, Ribas F, Diaz-Delfin J, Giralt M, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. J Biol Chem (2011) 286(19):16958–66. doi: 10.1074/jbc.M110.202390
60. Zhang T, Liu J, Tong Q, Lin L. SIRT3 acts as a positive autophagy regulator to promote lipid mobilization in adipocytes via activating AMPK. Int J Mol Sci (2020) 21(2):372. doi: 10.3390/ijms21020372
61. Wei T, Gao J, Huang C, Song B, Sun M, Shen W. SIRT3 (Sirtuin-3) prevents ang II (Angiotensin II)-induced macrophage metabolic switch improving perivascular adipose tissue function. Arterioscler Thromb Vasc Biol (2021) 41(2):714–30. doi: 10.1161/ATVBAHA.120.315337
62. Wei T, Huang G, Liu P, Gao J, Huang C, Sun M, et al. Sirtuin 3-mediated pyruvate dehydrogenase activity determines brown adipocytes phenotype under high-salt conditions. Cell Death Dis (2019) 10(8):614. doi: 10.1038/s41419-019-1834-4
63. Wu YT, Chi KT, Lan YW, Chan JC, Ma YS, Wei YH. Depletion of Sirt3 leads to the impairment of adipogenic differentiation and insulin resistance via interfering mitochondrial function of adipose-derived human mesenchymal stem cells. Free Radic Res (2018) 52(11-12):1398–415. doi: 10.1080/10715762.2018.1489130
64. Zaganjor E, Yoon H, Spinelli JB, Nunn ER, Laurent G, Keskinidis P, et al. SIRT4 is an early regulator of branched-chain amino acid catabolism that promotes adipogenesis. Cell Rep (2021) 36(2):109345. doi: 10.1016/j.celrep.2021.109345
65. Hong J, Li S, Wang X, Mei C, Zan L. Study of expression analysis of SIRT4 and the coordinate regulation of bovine adipocyte differentiation by SIRT4 and its transcription factors. Biosci Rep (2018) 38(6):BSR20181705. doi: 10.1042/bsr20181705
66. Laurent G, German NJ, Saha AK, de Boer VC, Davies M, Koves TR, et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell (2013) 50(5):686–98. doi: 10.1016/j.molcel.2013.05.012
67. Molinari F, Feraco A, Mirabilii S, Saladini S, Sansone L, Vernucci E, et al. SIRT5 inhibition induces brown fat-like phenotype in 3T3-L1 preadipocytes. Cells (2021) 10(5):1126. doi: 10.3390/cells10051126
68. Hong J, Mei C, Raza SHA, Khan R, Cheng G, Zan L. SIRT5 inhibits bovine preadipocyte differentiation and lipid deposition by activating AMPK and repressing MAPK signal pathways. Genomics (2020) 112(2):1065–76. doi: 10.1016/j.ygeno.2019.12.004
69. Wang G, Meyer JG, Cai W, Softic S, Li ME, Verdin E, et al. Regulation of UCP1 and mitochondrial metabolism in brown adipose tissue by reversible succinylation. Mol Cell (2019) 74(4):844–57 e7. doi: 10.1016/j.molcel.2019.03.021
70. Yu J, Sadhukhan S, Noriega LG, Moullan N, He B, Weiss RS, et al. Metabolic characterization of a Sirt5 deficient mouse model. Sci Rep (2013) 3:2806. doi: 10.1038/srep02806
71. Hong J, Mei C, Abbas Raza SH, Khan R, Cheng G, Zan L. SIRT6 cooperates with SIRT5 to regulate bovine preadipocyte differentiation and lipid metabolism via the AMPKα signaling pathway. Arch Biochem Biophys (2020) 681:108260. doi: 10.1016/j.abb.2020.108260
72. Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell (2010) 9(2):162–73. doi: 10.1111/j.1474-9726.2009.00544.x
73. Kuang JY, Zhang YW, Liu QH, Shen J, Pu SY, Cheng SH, et al. Fat-specific Sirt6 ablation sensitizes mice to high-fat diet–induced obesity and insulin resistance by inhibiting lipolysis. Diabetes (2017) 66:1159–71. doi: 10.2337/db16-1225/-/DC1
74. Lee Y, Ka SO, Cha HN, Chae YN, Kim MK, Park SY, et al. Myeloid sirtuin 6 deficiency causes insulin resistance in high-fat diet-fed mice by eliciting macrophage polarization toward an M1 phenotype. Diabetes (2017) 66(10):2659–68. doi: 10.2337/db16-1446
75. Yao L, Cui X, Chen Q, Yang X, Fang F, Zhang J, et al. Cold-inducible SIRT6 regulates thermogenesis of brown and beige fat. Cell Rep (2017) 20(3):641–54. doi: 10.1016/j.celrep.2017.06.069
76. Bang IH, Park D, Lee Y, Cho H, Park BH, Bae EJ. Sirtuin 6 promotes eosinophil differentiation by activating GATA-1 transcription factor. Aging Cell (2021) 20(7):e13418. doi: 10.1111/acel.13418
77. Tang Q, Gao Y, Liu Q, Yang X, Wu T, Huang C, et al. Sirt6 in pro-opiomelanocortin neurons controls energy metabolism by modulating leptin signaling. Mol Metab (2020) 37:100994. doi: 10.1016/j.molmet.2020.100994
78. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell (2010) 140(2):280–93. doi: 10.1016/j.cell.2009.12.041
79. Chen Q, Hao W, Xiao C, Wang R, Xu X, Lu H, et al. SIRT6 is essential for adipocyte differentiation by regulating mitotic clonal expansion. Cell Rep (2017) 18(13):3155–66. doi: 10.1016/j.celrep.2017.03.006
80. Song MY, Kim SH, Ryoo GH, Kim MK, Cha HN, Park SY, et al. Adipose sirtuin 6 drives macrophage polarization toward M2 through IL-4 production and maintains systemic insulin sensitivity in mice and humans. Exp Mol Med (2019) 51(5):1–10. doi: 10.1038/s12276-019-0256-9
81. Fang J, Ianni A, Smolka C, Vakhrusheva O, Nolte H, Kruger M, et al. Sirt7 promotes adipogenesis in the mouse by inhibiting autocatalytic activation of Sirt1. Proc Natl Acad Sci U.S.A. (2017) 114(40):E8352–E61. doi: 10.1073/pnas.1706945114
82. Yamaguchi S, Franczyk MP, Chondronikola M, Qi N, Gunawardana SC, Stromsdorfer KL, et al. Adipose tissue NAD(+) biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice. Proc Natl Acad Sci U.S.A. (2019) 116(47):23822–8. doi: 10.1073/pnas.1909917116
83. Nielsen KN, Peics J, Ma T, Karavaeva I, Dall M, Chubanava S, et al. NAMPT-mediated NAD(+) biosynthesis is indispensable for adipose tissue plasticity and development of obesity. Mol Metab (2018) 11:178–88. doi: 10.1016/j.molmet.2018.02.014
84. Franczyk MP, Qi N, Stromsdorfer KL, Li C, Yamaguchi S, Itoh H, et al. Importance of adipose tissue NAD+ biology in regulating metabolic flexibility. Endocrinology (2021) 162(3):bqab006. doi: 10.1210/endocr/bqab006
85. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab (2011) 14(4):528–36. doi: 10.1016/j.cmet.2011.08.014
86. Rappou E, Jukarainen S, Rinnankoski-Tuikka R, Kaye S, Heinonen S, Hakkarainen A, et al. Weight loss is associated with increased NAD(+)/SIRT1 expression but reduced PARP activity in white adipose tissue. J Clin Endocrinol Metab (2016) 101(3):1263–73. doi: 10.1210/jc.2015-3054
87. Wei X, Jia R, Wang G, Hong S, Song L, Sun B, et al. Depot-specific regulation of NAD(+)/SIRTs metabolism identified in adipose tissue of mice in response to high-fat diet feeding or calorie restriction. J Nutr Biochem (2020) 80:108377. doi: 10.1016/j.jnutbio.2020.108377
88. Okabe K, Nawaz A, Nishida Y, Yaku K, Usui I, Tobe K, et al. NAD+ metabolism regulates preadipocyte differentiation by enhancing alpha-Ketoglutarate-Mediated histone H3K9 demethylation at the PPARgamma promoter. Front Cell Dev Biol (2020) 8:586179. doi: 10.3389/fcell.2020.586179
89. Stromsdorfer KL, Yamaguchi S, Yoon MJ, Moseley AC, Franczyk MP, Kelly SC, et al. NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep (2016) 16(7):1851–60. doi: 10.1016/j.celrep.2016.07.027
90. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab (2012) 15(6):838–47. doi: 10.1016/j.cmet.2012.04.022
91. Kim MB, Pham TX, vanLuling M, Kostour V, Kang H, Corvino O, et al. Nicotinamide riboside supplementation exerts an anti-obesity effect and prevents inflammation and fibrosis in white adipose tissue of female diet-induced obesity mice. J Nutr Biochem (2022) 107:109058. doi: 10.1016/j.jnutbio.2022.109058
92. Hwang JW, Yao H, Caito S, Sundar IK, Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med (2013) 61:95–110. doi: 10.1016/j.freeradbiomed.2013.03.015
93. Zhou S, Tang X, Chen HZ. Sirtuins and insulin resistance. Front Endocrinol (2018) 9:748. doi: 10.3389/fendo.2018.00748
94. Gomes P, Fleming Outeiro T, Cavadas C. Emerging role of sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol Sci (2015) 36(11):756–68. doi: 10.1016/j.tips.2015.08.001
95. Wu Y, Gao WN, Xue YN, Zhang LC, Zhang JJ, Lu SY, et al. SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells. Exp Cell Res (2018) 367(2):137–49. doi: 10.1016/j.yexcr.2018.03.030
96. Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis (2010) 11(1):55–62. doi: 10.1111/j.1751-2980.2009.00416.x
97. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 27(24):8807–14. doi: 10.1128/MCB.01636-07
98. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem (2005) 280(14):13560–7. doi: 10.1074/jbc.M414670200
99. Kurylowicz A, Owczarz M, Polosak J, Jonas MI, Lisik W, Jonas M, et al. SIRT1 and SIRT7 expression in adipose tissues of obese and normal-weight individuals is regulated by microRNAs but not by methylation status. Int J Obes (2016) 40(11):1635–42. doi: 10.1038/ijo.2016.131
100. Gillum MP, Erion DM, Shulman GI. Sirtuin-1 regulation of mammalian metabolism. Trends Mol Med (2011) 17(1):8–13. doi: 10.1016/j.molmed.2010.09.005
101. Moschen AR, Wieser V, Gerner RR, Bichler A, Enrich B, Moser P, et al. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol (2013) 59(6):1315–22. doi: 10.1016/j.jhep.2013.07.027
102. Jukarainen S, Heinonen S, Ramo JT, Rinnankoski-Tuikka R, Rappou E, Tummers M, et al. Obesity is associated with low NAD(+)/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic twins. J Clin Endocrinol Metab (2016) 101(1):275–83. doi: 10.1210/jc.2015-3095
103. Veronica MJ, Nancy CE, Eduardo RV, Mariela VC, Margarita BE, Víctor MRR, et al. Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity. Diabetes Metab Syndr (2019) 13(1):582–9. doi: 10.1016/j.dsx.2018.11.011
104. Jokinen R, Pirnes-Karhu S, Pietilainen KH, Pirinen E. Adipose tissue NAD(+)-homeostasis, sirtuins and poly(ADP-ribose) polymerases-important players in mitochondrial metabolism and metabolic health. Redox Biol (2017) 12:246–63. doi: 10.1016/j.redox.2017.02.011
105. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev (2008) 22(13):1753–7. doi: 10.1101/gad.1650608
106. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science (2004) 306(5704):2105–8. doi: 10.1126/science.1101731
107. Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell (2007) 6(4):505–14. doi: 10.1111/j.1474-9726.2007.00304.x
108. Kanfi Y, Shalman R, Peshti V, Pilosof SN, Gozlan YM, Pearson KJ, et al. Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett (2008) 582(5):543–8. doi: 10.1016/j.febslet.2008.01.019
109. Kanfi Y, Peshti V, Gozlan YM, Rathaus M, Gil R, Cohen HY. Regulation of SIRT1 protein levels by nutrient availability. FEBS Lett (2008) 582(16):2417–23. doi: 10.1016/j.febslet.2008.06.005
110. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 126(5):941–54. doi: 10.1016/j.cell.2006.06.057
111. Wronska A, Lawniczak A, Wierzbicki PM, Kmiec Z. Age-related changes in sirtuin 7 expression in calorie-restricted and refed rats. Gerontology (2016) 62(3):304–10. doi: 10.1159/000441603
112. Liu Z, Gu H, Gan L, Xu Y, Feng F, Saeed M, et al. Reducing Smad3/ATF4 was essential for Sirt1 inhibiting ER stress-induced apoptosis in mice brown adipose tissue. Oncotarget (2017) 8(6):9267–79. doi: 10.18632/oncotarget.14035
113. Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol (2019) 20(4):242–58. doi: 10.1038/s41580-018-0093-z
114. Ye X, Li MT, Hou TY, Gao T, Zhu WG, Yang Y. Sirtuins in glucose and lipid metabolism. Oncotarget (2017) 8:1845–59. doi: 10.18632/oncotarget.12157
115. Porter LC, Franczyk MP, Pietka T, Yamaguchi S, Lin JB, Sasaki Y, et al. NAD(+)-dependent deacetylase SIRT3 in adipocytes is dispensable for maintaining normal adipose tissue mitochondrial function and whole body metabolism. Am J Physiol Endocrinol Metab (2018) 315(4):E520–E30. doi: 10.1152/ajpendo.00057.2018
116. de Pinho L, Andrade JM, Paraiso A, Filho AB, Feltenberger JD, Guimaraes AL, et al. Diet composition modulates expression of sirtuins and renin-angiotensin system components in adipose tissue. Obesity (2013) 21(9):1830–5. doi: 10.1002/oby.20305
117. Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK, McCall CE. Sirtuins link inflammation and metabolism. J Immunol Res (2016) 2016:8167273. doi: 10.1155/2016/8167273
118. Galli M, Van Gool F, Leo O. Sirtuins and inflammation: Friends or foes? Biochem Pharmacol (2011) 81(5):569–76. doi: 10.1016/j.bcp.2010.12.010
119. Vachharajani V, McCall CE. Sirtuins: potential therapeutic targets for regulating acute inflammatory response? Expert Opin Ther Targets (2020) 24(5):489–97. doi: 10.1080/14728222.2020.1743268
120. Mariani S, Di Rocco G, Toietta G, Russo MA, Petrangeli E, Salvatori L. Sirtuins 1-7 expression in human adipose-derived stem cells from subcutaneous and visceral fat depots: influence of obesity and hypoxia. Endocrine (2017) 57(3):455–63. doi: 10.1007/s12020-016-1170-8
121. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol (2011) 29:415–45. doi: 10.1146/annurev-immunol-031210-101322
122. Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, et al. SirT1 regulates adipose tissue inflammation. Diabetes (2011) 60(12):3235–45. doi: 10.2337/db11-0616/-/DC1
123. Escalona-Garrido C, Vazquez P, Mera P, Zagmutt S, Garcia-Casarrubios E, Montero-Pedrazuela A, et al. Moderate SIRT1 overexpression protects against brown adipose tissue inflammation. Mol Metab (2020) 42:101097. doi: 10.1016/j.molmet.2020.101097
124. Jiang H, Westerterp M, Wang C, Zhu Y, Ai D. Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia (2014) 57(11):2393–404. doi: 10.1007/s00125-014-3350-5
125. Han MS, Jung DY, Morel C, Lakhani SA, Kim JK, Flavell RA, et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science (2013) 339(6116):218–22. doi: 10.1126/science.1227568
126. Zullo A, Mancini FP, Schleip R, Wearing S, Klingler W. Fibrosis: Sirtuins at the checkpoints of myofibroblast differentiation and profibrotic activity. Wound Repair Regener (2021) 29(4):650–66. doi: 10.1111/wrr.12943
127. Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: Promises, achievements, and challenges. Pharmacol Ther (2018) 188:140–54. doi: 10.1016/j.pharmthera.2018.03.004
128. Westerberg G, Chiesa JA, Andersen CA, Diamanti D, Magnoni L, Pollio G, et al. Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers. Br J Clin Pharmacol (2015) 79(3):477–91. doi: 10.1111/bcp.12513
129. Sussmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with huntington's disease. Br J Clin Pharmacol (2015) 79(3):465–76. doi: 10.1111/bcp.12512
130. Song J, Yang B, Jia X, Li M, Tan W, Ma S, et al. Distinctive roles of sirtuins on diabetes, protective or detrimental? Front Endocrinol (2018) 9:724. doi: 10.3389/fendo.2018.00724
131. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab (2011) 14(5):612–22. doi: 10.1016/j.cmet.2011.10.002
132. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab (2012) 16(5):658–64. doi: 10.1016/j.cmet.2012.09.015
133. Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Modified resveratrol longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res (2011) 31(11):842–7. doi: 10.1016/j.nutres.2011.09.028
134. Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, et al. Assessing colonic exposure, safety, and clinical activity of SRT2104, a novel oral SIRT1 activator, in patients with mild to moderate ulcerative colitis. Inflamm Bowel Dis (2016) 22(3):607–14. doi: 10.1097/MIB.0000000000000597
Keywords: Sirtuins, obesity, adipose tissue remodeling, inflammation, fibrosis
Citation: Chen J, Lou R, Zhou F, Li D, Peng C and Lin L (2022) Sirtuins: Key players in obesity-associated adipose tissue remodeling. Front. Immunol. 13:1068986. doi: 10.3389/fimmu.2022.1068986
Received: 13 October 2022; Accepted: 09 November 2022;
Published: 24 November 2022.
Edited by:
Zhihao Jia, Purdue University, United StatesReviewed by:
Dimitri Papukashvili, Southern University of Science and Technology, ChinaShintaro Yamaguchi, Keio University School of Medicine, Japan
Copyright © 2022 Chen, Lou, Zhou, Li, Peng and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cheng Peng, cGVuZ2NoZW5nY2hlbmdkdUAxMjYuY29t; Ligen Lin, bGlnZW5sQHVtLmVkdS5tbw==